Dignitana, a Sweden-based company, has announced a new partnership with OncoMedical, granting it exclusive distribution rights for the DigniCap Scalp Cooling System in Switzerland and Liechtenstein.
The agreement is expected to enhance the availability of the DigniCap solution, which helps minimise hair loss from chemotherapy.
OncoMedical, which offers oncology, pain therapy and palliative care medical technology products, has committed to purchasing a minimum of eight DigniCap Delta devices and associated patient consumables in 2024.
The initial order of three devices is expected to be delivered in January 2024.
The partnership aims to not only introduce the DigniCap Delta system to new facilities but also to upgrade existing Dignitana technology available in 11 clinics across Switzerland.
OncoMedical CEO Simon Dätwyler said: “Scalp cooling with DigniCap Delta is a significant advancement in quality of life for cancer patients.
“Customers want the most advanced treatments to ensure optimal patient outcomes. We are happy to add DigniCap to our suite of top tier medical technologies and are eager to expand availability of DigniCap in this region.”
Approved by the US Food and Drug Administration, the DigniCap Scalp Cooling System is designed to reduce hair loss caused by chemotherapy in patients with solid tumours, including breast, prostate and gynecological cancers.
The system addresses a critical need for supportive cancer care in the region.
Dignitana CEO Catarina Löwenadler said: “OncoMedical shares our commitment to excellence in technology, customer service and patient care.
“As we continue to expand patient access, Dignitana is strengthened by utilising local market experts like OncoMedical to ensure customers receive the best possible service and attention.”
